Summary
The product Sermorelin 2 mg, manufactured by Biogenix Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number Unknown, was submitted by the reseller biogenixpharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Sermorelin, with a concentration of 1.60 mg, which is 20% below the labeled claim of 2 mg. The product’s purity was determined to be 98.722%.
The testing process began on 11 August 2024, with the sample received on 22 August 2024, and analysis completed on 23 August 2024. While the purity remains high, the underdosing raises concerns about the product’s consistency. Scrutiny of reseller-submitted samples remains essential to ensure reliability, as resellers may select specific batches that meet high-quality standards. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Biogenix Pharma
- Product Name: Sermorelin 2 mg
- Active Ingredient: Sermorelin
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #47816
- Testing Ordered: 11 August 2024
- Sample Received: 22 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: biogenixpharma (Reseller)
- Analysis Paid For By: biogenixpharma
Testing Results
- Specification: 2 mg (as stated on the label)
- Measured Concentration: 1.60 mg
- Accuracy: 80% (20% below the label claim)
- Purity: 98.722%
Verification Details
- Verification URL: https://janoshik.com/tests/47816_6G7XVDIS6YRG
Evaluation of Reseller-Submitted Testing
This analysis highlights the high purity of the tested product but also raises concerns due to its underdosing. Since the reseller biogenixpharma submitted and funded the test, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that Sermorelin 2 mg is significantly underdosed, with a measured concentration of 1.60 mg, but maintains a high purity of 98.722%. While this batch exhibits good quality control in terms of purity, the lower concentration underscores the importance of further testing to ensure accurate dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
